Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2020 – AML
ASH 2020 – AML
Successful Engraftment in Patients with Active R/R AML After Personalized Iodine-131-Apamistamab, an Anti-CD45 Radioimmunotherapy
ASH 2020 – AML
Among patients with relapsed/refractory acute myeloid leukemia (R/R AML), patient-specific doses of iodine-131-apamistamab resulted in consistent engraftment following allogeneic hematopoietic stem-cell transplantation.
Read More ›
A Phase 3 Comparison of Azacitidine ± Gilteritinib for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia Patients
ASH 2020 – AML
No new safety signals associated with gilteritinib were found in a study comparing gilteritinib + azacitidine with azacitidine alone in patients with newly diagnosed,
FLT3
-mutated AML. A composite response rate of 67% was found among patients in the safety cohort receiving gilteritinib + azacitidine.
Read More ›
CPX-351 plus Venetoclax in Patients with Acute Myeloid Leukemia: A Phase 2 Study
ASH 2020 – AML
CPX-351 plus 7 days of venetoclax was tolerable and demonstrated encouraging activity in patients with relapsed/refractory acute myeloid leukemia.
Read More ›
Treating First AML Low Blast Count Relapse with Escalated Dosing Schedules of CC-486 Is Effective and Well-Tolerated
ASH 2020 – AML
An escalated 21-day CC-486 (oral azacitidine) dosing regimen was well-tolerated and restored remission in approximately 25% of patients with acute myeloid leukemia (AML) who relapsed with 5% to 15% blasts on-study in the QUAZAR AML-001 trial.
Read More ›
A Comparison of the Effectiveness of Glasdegib versus Venetoclax in Combination with Low-Dose Ara-C
ASH 2020 – AML
Overall survival hazard ratios based on adjusted simulated treatment comparisons numerically, but not statistically, favored glasdegib plus low-dose cytarabine (LDAC) over venetoclax plus LDAC.
Read More ›
Venetoclax plus Decitabine versus Intensive Chemotherapy for Treating Relapsed/Refractory AML
ASH 2020 – AML
As salvage therapy in younger patients with relapsed/refractory acute myeloid leukemia (AML), the efficacy of 10-day decitabine + venetoclax is comparable to intensive chemotherapy regimens and is an appropriate bridge to allogeneic stem-cell transplantation.
Read More ›
FLAG-IDA Intensive Induction/Consolidation plus Venetoclax in Newly Diagnosed or R/R AML Patients
ASH 2020 – AML
Across multiple acute myeloid leukemia (AML) subgroups, venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile, representing an attractive option as a bridge to allo-SCT for adverse-risk, newly diagnosed, and relapsed/refractory (R/R) AML patients.
Read More ›
Selinexor plus 7+3 and HDAC Consolidation Is Highly Active in Older Adults with Newly Diagnosed Acute Myeloid Leukemia
ASH 2020 – AML
In older patients with de novo acute myeloid leukemia, the combination of selinexor with standard induction and consolidation therapy appears highly active.
Read More ›
After No Response to Enasidenib, Adding Azacitidine Is Effective for Older Patients with IDH2-Mutated AML
ASH 2020 – AML
In patients with newly diagnosed
IDH2
mut
acute myeloid leukemia (AML), treatment with enasidenib was associated with low early death and high complete response and complete response with incomplete hematologic recovery rates and yielded durable remission.
Read More ›
Adding Venetoclax to Cladribine + Low-Dose Cytarabine Alternating with Azacitidine Is Effective and Well-Tolerated by Older Patients with AML
ASH 2020 – AML
Among patients with acute myeloid leukemia (AML), venetoclax added to a low-intensity backbone of cladribine plus low-dose Ara-C alternating with 5-azacitidine was an effective, well-tolerated regimen.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us